On May 23, 2024, Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, announced the completion of a $33 million Series B financing. The round was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures. Wilson Sonsini Goodrich & Rosati advised Atropos Health on the transaction.

Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. The additional capital will be used to further scale the automation of high-quality, personalized real-world evidence for value-based care, expand their Atropos Evidence™ network, and boost investment in ChatRWD, the first AI-powered chat to database application built on GENEVA OS™. 

The Wilson Sonsini team that advised Atropos Health on the transaction includes Lang Liu, Mark Bass, Alex Youssef, Won Gi Chong, and Jing Zhang.

For more information, please see Atropos Health's news release. Additional coverage can be found on Business Insider, Crain's, and Fierce Healthcare.